TNXP Company Profile and Key Details

Q: Who are the executives of TNXP?

Ms. Siobhan Fogarty B.Sc., M.Sc.Executive Vice President of Product Devel.Dr. Darryl Rideout Ph.D.Executive Vice President of Experimental ChemistryMr. Bradley Saenger CPA, CPAChief Financial Officer & TreasurerMrs. Jessica Edgar MorrisChief Operating OfficerDr. Gregory M. Sullivan M.D.Chief Medical Officer & Sec.Dr. Herbert W. Harris M.D., Ph.D.Executive Vice President of Translational MedicineDr. Bruce L. Daugherty M.B.A., Ph.D.Executive Vice President of ResearchDr. Daniel J. Clauw M.D.ConsultantDr. Sina Bavari Ph.D.Executive Vice President of Infectious Disease R&DDr. Zeil Rosenberg M.D., M.P.H.Executive Vice President of MedicalMr. Bradley Saenger C.P.A., CPAChief Financial Officer & TreasurerDr. Seth Lederman M.D.Co-Founder, Pres, Chief Executive Officer & Chairman

NASDAQ : TNXP

Tonix Pharmaceuticals Holding

$11.98

-0.12-0.99%

At Close 4:00 PM

66.59

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Tonix Pharmaceuticals Holding Corp. (TNXP) stock declined over -0.99%, trading at $11.98 on NASDAQ, down from the previous close of $12.10. The stock opened at $12.40, fluctuating between $11.96 and $13.57 in the recent session.

Stock Snapshot

12.1

Prev. Close

190.97M

Market Cap

11.96

Day Low

-0.83

P/E Ratio

-14.36

EPS (TTM)

-3.44

Cash Flow per Share

12.4

Open

15.94M

Number of Shares

13.57

Day High

99.95%

Free Float in %

3.32

Book Value

715.91K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 25, 2026	12.35	13.57	11.95	11.98	717.69K
Jun 24, 2026	11.96	12.30	11.84	12.10	390.8K
Jun 23, 2026	11.79	12.58	11.78	11.96	466.31K
Jun 22, 2026	11.95	12.54	11.93	12.20	395.85K
Jun 18, 2026	12.48	12.87	11.89	12.01	567.03K
Jun 17, 2026	11.65	12.59	11.52	12.20	559.2K
Jun 16, 2026	11.52	11.78	11.12	11.63	371.89K
Jun 15, 2026	11.70	12.02	11.48	11.52	422.36K
Jun 12, 2026	10.65	11.40	10.41	11.35	675.86K
Jun 11, 2026	11.00	11.01	10.03	10.65	1.05M
Jun 10, 2026	11.98	12.78	10.87	10.96	1.15M
Jun 09, 2026	11.72	12.03	11.03	11.46	540.22K
Jun 08, 2026	11.54	12.27	11.46	11.71	471.19K
Jun 05, 2026	11.87	11.91	10.87	11.07	478.48K
Jun 04, 2026	11.28	12.42	11.21	11.88	580.96K
Jun 03, 2026	11.69	11.69	11.31	11.40	359.96K
Jun 01, 2026	12.30	12.54	12.12	12.29	325.72K
May 29, 2026	12.63	12.67	12.08	12.33	420.55K
May 28, 2026	12.29	12.80	12.12	12.64	381.59K
May 27, 2026	12.80	13.04	12.02	12.15	677.49K

Contact Details

Chatham, NJ 07928

United States

https://www.tonixpharma.com 862 799 8599

About Company

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.

Stock Peers

ARGX

36.15+4.24%

argenx SE$888.65 REGN

-3.29-0.53%

Regeneron Pharmaceuticals, Inc.$620.14 UTHR

-6.51-1.18%

United Therapeutics Corporation$543.39 MDGL

4.03+0.79%

Madrigal Pharmaceuticals, Inc.$513.79 VRTX

4.98+1.05%

Vertex Pharmaceuticals Incorporated$480.18 KRYS

12.3+3.54%

Krystal Biotech, Inc.$359.93 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

18.92+6.12%

Praxis Precision Medicines, Inc.$327.86 LGND

11.01+3.86%

Ligand Pharmaceuticals Incorporated$295.92 ALNY

-0.89-0.30%

Alnylam Pharmaceuticals, Inc.$293.17

Company Overview

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) closed at $11.98 USD, losing -$0.12 (-0.99%) from the previous close of $12.10. The stock is currently mid-range between its 52-week high and low $10.03 and $69.97. With a market capitalization of about $190.97 million, Tonix Pharmaceuticals Holding Corp. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.68). Key stats such as the average daily volume over the past year has been around 481.47 thousand shares, in line with its 52-week average. Headquartered in Chatham, NJ, Tonix Pharmaceuticals Holding Corp. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Seth Lederman, the company employs approximately 81 people and listed since May 10, 2012. Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage.

Technical Performance

TNXP has shown mixed momentum, gaining 8.05% over the past week and -8.49% over the past quarter, though year-to-date performance is up 9.09%. Short-term trend indicators are bullishly aligned (SMA20 -7.8%, SMA50 -12.04%, SMA200 -45.59%). The stock’s 14-day RSI is 39.18 (weak momentum), while the ATR of 0.91 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -79.38% below its high and over 113.46% above its low. Average 10-day trading volume of 495.54 thousand shares is in line with the 3-month average of 476.57 thousand, indicating normal recent market interest.

Valuation Metrics

Tonix Pharmaceuticals Holding Corp. trades at a P/E ratio of -0.83, slightly below the S&P 500 average, with a price-to-sales ratio of 11.0 and a price-to-book ratio of 0.73 suggesting the stock is closer to book value. The P/FCF stands at -1.46, also above market averages.

Dividend & Fair Value

Tonix Pharmaceuticals Holding Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $12.38. This means the shares are trading near this model’s fair value.

Earnings & Analyst Outlook

Tonix Pharmaceuticals Holding Corp. generated EPS of -$986.99 over the past year. Five-year average earnings growth is 73.03%. Wall Street analysts project EPS growth of 74.04% annually over the next five years. The latest quarter delivered EPS of -$2.93. The next quarter is forecast at -$3.19. Next year's EPS is expected at $68.63. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $26.00 to $22.00. The high target offers 117.03% upside. The low target suggests 83.64% downside. The mean target is $24.00. This offers 100.33% upside. Tonix Pharmaceuticals Holding Corp. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 15.35%. The prior quarter beat by 25.95%. Over the last six quarters, Apple has recorded several small beats. These include 56.82% in March 18, 2025.

Shareholding & Insider Activity

Tonix Pharmaceuticals Holding Corp. has 8.77 million shares outstanding. The public float is 8.76 million shares, elevated short interest at 13.39% of float. This equals 1.17 million shares. The short ratio is 0.6 days. Institutional investors hold 45.69% of the float. Insiders own 0.13%. DAUGHERTY BRUCE holds 100.00 thousand shares, Saks Samuel R has 63.55 thousand shares and MARIO ERNEST has 50.00 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Tonix Pharmaceuticals Holding generated $7.77M in revenue, or $0.46 per share. Gross margin was -16.27%, operating margin -1523.94%, and net profit margin -1501.78%. Returns are negative, with ROA at -75.53% and ROE at -110.55%.
On valuation metrics, Tonix Pharmaceuticals Holding trades at a P/E of -0.83, P/S of 11.00 and P/B of 0.73. The current ratio is 6.99 and quick ratio is 6.86. Operationally, the company’s inventory turnover is 2.28 and cash conversion cycle is -80.09 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -97.35.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Tonix Pharmaceuticals Holding posted revenue of $7.77M, down slightly from $0.00 in the prior quarter. Gross profit was - $1.26M (margin -16.27%). Operating income was - $118.38M (margin -1523.9%). Net income was- $116.66M (EPS - $6.85).
The company ended the quarter with $24.95M in cash and short-term investments, a total debt of $9.81M, and net debt of - $15.14M. Total assets were $154.46M, with equity of $105.53M. Financials further reflected weakness, with operating cash flow of - $102.00M, free cash flow of - $109.90M, and capital expenditures of - $7.90M.

Price Forecast & Outlook

Our AI price prediction model suggests that Tonix Pharmaceuticals Holding Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.01%, with price expected at $11.38 by July 09, 2026, within a range of $10.55 to $12.19 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by September 22, 2026, with a range of $0.00 to $115.78. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by June 25, 2027, within a range of $0.00 to $4.75 thousand.

Key Takeaways

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares are flat 9.09% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Tonix Pharmaceuticals Holding Corp. trading at a premium to the broader market with a P/E of -0.83. Analyst sentiment is cautious, with the majority of ratings in Strong Buy territory and a mean price target of $17.04, suggesting 42.24% upside. Our AI forecast model points to short-term weakness (-5.01% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Tonix Pharmaceuticals Holding Corp. (TNXP) stock price?

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) stock price is $11.98 in the last trading session. During the trading session, TNXP stock reached the peak price of $13.57 while $11.96 was the lowest point it dropped to. The percentage change in TNXP stock occurred in the recent session was -0.99% while the dollar amount for the price change in TNXP stock was - $0.12.

TNXP's industry and sector of operation?

The NASDAQ listed TNXP is part of Biotechnology industry that operates in the broader Healthcare sector. Tonix Pharmaceuticals Holding Corp. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of TNXP?

Ms. Siobhan Fogarty B.Sc., M.Sc.
Executive Vice President of Product Devel.
Dr. Darryl Rideout Ph.D.
Executive Vice President of Experimental Chemistry
Mr. Bradley Saenger CPA, CPA
Chief Financial Officer & Treasurer
Mrs. Jessica Edgar Morris
Chief Operating Officer
Dr. Gregory M. Sullivan M.D.
Chief Medical Officer & Sec.
Dr. Herbert W. Harris M.D., Ph.D.
Executive Vice President of Translational Medicine
Dr. Bruce L. Daugherty M.B.A., Ph.D.
Executive Vice President of Research
Dr. Daniel J. Clauw M.D.
Consultant
Dr. Sina Bavari Ph.D.
Executive Vice President of Infectious Disease R&D
Dr. Zeil Rosenberg M.D., M.P.H.
Executive Vice President of Medical
Mr. Bradley Saenger C.P.A., CPA
Chief Financial Officer & Treasurer
Dr. Seth Lederman M.D.
Co-Founder, Pres, Chief Executive Officer & Chairman

How TNXP did perform over past 52-week?

TNXP's closing price is 19.44% higher than its 52-week low of $10.03 where as its distance from 52-week high of $69.97 is -82.88%.

How many employees does TNXP have?

Number of TNXP employees currently stands at 81.

Link for TNXP official website?

Official Website of TNXP is: https://www.tonixpharma.com

How do I contact TNXP?

TNXP could be contacted at phone 862 799 8599 and can also be accessed through its website. TNXP operates from 26 Main Street, Chatham, NJ 07928, United States.

How many shares of TNXP are traded daily?

TNXP stock volume for the day was 715.91K shares. The average number of TNXP shares traded daily for last 3 months was 481.47K.

What is the market cap of TNXP currently?

The market value of TNXP currently stands at $190.97M with its latest stock price at $11.98 and 15.94M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	81
Beta	1.68
Sales or Revenue	$7.77M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

TNXP Company Profile and Key Details

Tonix Pharmaceuticals Holding

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook